



18:30- 19:45 **EGFR TARGETED THERAPIES**

Chairs: Γ. Κουμάκης, **N. Κεντεποζίδης**

Presenter 1: **T. Μπηλίδας** (15 min)

- OA 05.01 FIRST-LINE DACOMITINIB VERSUS GEFITINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER WITH EGFR MUTATION SUBGROUPS
- OA 05.02 OSIMERTINIB VS SOC EGFR-TKI AS FIRST-LINE TREATMENT IN PATIENTS WITH EGFRM ADVANCED NSCLC (FLAURA): PLASMA CtDNA ANALYSIS
- OA 07.05 SERIAL BIOPSIES IN PATIENTS WITH EGFR-MUTANT NSCLC HIGHLIGHT THE SPATIAL AND TEMPORAL HETEROGENEITY OF RESISTANCE MECHANISMS

19:45- 20:30 **EDUCATIONAL SESSION**

Chairs: **X. Κουρούσης, A. Κωτσάκης**

Presenter: **N. Κεντεποζίδης**

ES 04.02 RESISTANCE MECHANISMS IN TKI

Q & A